137 related articles for article (PubMed ID: 36327674)
21. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
Huang L; Zhang X; Bai Y; Chua KLM; Xie Y; Shu X; Long B; Fan C; Lim DWT; Tan SH; Wee JTS; Wang Y; Wu Y; Chua MLK
Oral Oncol; 2021 Apr; 115():105222. PubMed ID: 33610004
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
Zhou T; Yang Y; Ma S; Lin L; Zhou T; Zhang C; Ding X; Wang R; Feng G; Chen Y; Xu R; Huang Y; Zhang L
ESMO Open; 2021 Dec; 6(6):100313. PubMed ID: 34837744
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
25. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
Hoff CO; Manzi J; Lazar Neto F; Ferrarotto R
JAMA Otolaryngol Head Neck Surg; 2024 May; ():. PubMed ID: 38814585
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of locoregional radiotherapy plus chemotherapy vs. chemotherapy alone in metastatic nasopharyngeal carcinoma: a meta-analysis.
Wang G; Shen L
Ann Palliat Med; 2021 Mar; 10(3):2584-2595. PubMed ID: 33474951
[TBL] [Abstract][Full Text] [Related]
27. A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma.
Zhang Y; Luo F; Ma YX; Liu QW; Yang YP; Fang WF; Huang Y; Zhou T; Li J; Pan HM; Yang L; Qin SK; Zhao HY; Zhang L
Oncologist; 2022 Jun; 27(6):e453-e462. PubMed ID: 35445718
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
[TBL] [Abstract][Full Text] [Related]
30. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Tao L; Zhang H; An G; Lan H; Xu Y; Ge Y; Yao J
Front Oncol; 2021; 11():739263. PubMed ID: 34722290
[TBL] [Abstract][Full Text] [Related]
31. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
32. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma.
Sato H; Fushimi C; Okada T; Matsuki T; Kondo T; Omura GO; Miura K; Yamashita T; Okamoto I; Tsukahara K
In Vivo; 2020; 34(5):2967-2972. PubMed ID: 32871839
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
36. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
Liu L; Zhang Y; Wei J; Chen Z; Yu J
J Cancer; 2019; 10(4):799-809. PubMed ID: 30854085
[No Abstract] [Full Text] [Related]
37. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
38. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
40. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
